287
Views
20
CrossRef citations to date
0
Altmetric
Original Article

The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma

, , , &
Pages 28-33 | Published online: 27 Jul 2010

References

  • Juweid ME, Stroobants S, Hoekstra OS, et al Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma. J Clin Oncol 2007;25:571–578.
  • Zijlstra JM, Lindauer-van der WG, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 2006;91:522–529.
  • Cheson BD, Pfistner B, Juweid ME, et al Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
  • Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 2006;24:146–150.
  • Tang B, Malysz J, Douglas-Nikitin V, et al Correlating metabolic activity with cellular proliferation in follicular lymphomas. Mol Imaging Biol 2009;11:296–302.
  • Wirth A, Foo M, Seymour JF, Macmanus MP, Hicks RJ. Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2008;71:213–219.
  • Zinzani PL, Stefoni V, Tani M, et al Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:1781–1787.
  • Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009;50:1257–1260.
  • Lin C, Itti E, Haioun C, et al Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007;48:1626–1632.
  • Itti E, Lin C, Dupuis J, et al Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009;50:527–533.
  • Horning SJ, Juweid ME, Schoder H, et al Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 2010;115:775–777.
  • Haioun C, Itti E, Rahmouni A, et al [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376–1381.
  • Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514–1523.
  • Spaepen K, Stroobants S, Dupont P, et al Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356–1363.
  • Brusamolino E, Baio A, Orlandi E, et al Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: a single-institution 15-year follow-up. Clin Cancer Res 2006;12:6487–6493.
  • Connors JM. Controversy I: do we need radiotherapy in early Hodgkin lymphoma? Ann Oncol 2008;19 (Suppl. 4): (Abstract 005).
  • Radford J, O'Doherty M, Barrington S, et al Results of the 2nd planned interim analysis of the RAPID trial (involved field radiotherapy versus no further treatment) in patients with clinical stages 1A and 2A Hodgkin lymphoma and a ‘negative’ FDG-PET scan after 3 cycles ABVD. Blood 2008;112 (Suppl.): (Abstract 369).
  • Sehn LH, Savage KJ, Hoskins P, et al Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone. Ann Oncol 2008;19 (Suppl.): (Abstract 052).
  • Jost LM, Stahel RA. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of Hodgkin's disease. Ann Oncol 2005;16 (Suppl.) 1: i54–i55.
  • Kobe C, Dietlein M, Franklin J, et al Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008;112:3989–3994.
  • Picardi M, De RA, Pane F, et al Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007;48:1721–1727.
  • Savage KJ, Connors JM, Wilson D, et al FDG-PET guided consolidative radiotherapy in patients with advanced stage Hodgkin lymphoma with residual abnormalities on post chemotherapy CT scan. Blood 2007;110 (Suppl.): (Abstract 213).
  • Lee TS, Ahn SH, Moon BS, et al Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats. Nucl Med Biol 2009;36:681–686.
  • Herrmann K, Wieder HA, Buck AK, et al Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 2007;13:3552–3558.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.